Anupam Rasayan India Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/j3xp2dqs8vorul37k175d22o.pdf

Key Takeaways


Diversification & Revenue Mix Shift

Anand Desai: "Our dependence on agrochemicals has reduced from 76% revenue contribution in FY '22 to 55% in FY '26."

Bliss GVS Pharma Acquisition

Gopal Agrawal: "Our vision is to create a dedicated pharmaceutical platform through Bliss GVS, which will serve as a primary vehicle for our future pharma CDMO and CMO opportunities."

Jayhawk & Manufacturing Footprint


Stand-Alone Growth & Asset Utilization

Vishal Thakkar: "A growth of 20% to 25% or 30% growth rate over the next 3 to 5 years on a CAGR basis is something that we should be striving for and we should be looking at, and we feel reasonably confident on that performance."

Cash Flow & Balance Sheet


Platform Strategy & Competitive Positioning

Vishal Thakkar: "The larger the value chain that I can cover and offer to my customer, better -- and a better probability and better traction that I can see with my customer, better is the kind of engagement that I can have."

Guidance & Commitments

CommitmentSpecificsTimeline
Stand-alone revenue CAGR20-30% CAGRNext 3-5 years
Peak revenue from current gross block~INR3,500 crNo specific date; current capacity sufficient
Bliss capacity utilizationRamp from 30% to 60-70%Near-to-medium term
Bliss synergy resultsInitial results from CDMO, US, Europe, India expansion6-12 months; larger results in 18 months
Bliss EPS accretionEPS accretive from day oneFrom consummation
Bliss value creationFaster than Tanfac (which took 4 years)No specific date
Working capitalFurther improvementFY27
Stand-alone tax rate~25%Going forward
CapexNo major capex envisagedNear future
Bliss transaction consummationSEBI approval and open offer results2-3 months estimated

Key Metrics

MetricQ4 FY26
Consolidated total income₹639 cr, up 26% YoY from ₹506 cr
Consolidated revenue from operations (FY26)₹2,384 cr, up 65% YoY from ₹1,448 cr
Consolidated EBITDA (FY26)₹543 cr, margin of 23% vs ₹412 cr in FY25
Consolidated EBITDA (Q4)₹141 cr, margin of 22% vs ₹150 cr in Q4 FY25
Consolidated PAT (FY26)₹222 cr, margin of 9% vs ₹160 cr in FY25
Consolidated PAT (Q4)₹56 cr, margin of 9% vs ₹63 cr in Q4 FY25
Operating cash flow (FY26)₹334 cr consolidated, ₹274 cr standalone
Capex (FY26)₹315 cr, last leg of capex program; no major capex expected near-term
Standalone revenue mix (FY26)Agrochemicals 55%, Pharma 20%, Performance Materials 18%, Personal Care 7%
Pharma revenue (FY26 standalone)₹339 cr, 15-fold growth from ₹21 cr in FY22
Performance materials revenue (FY26 standalone)₹305 cr, threefold growth from ₹97 cr in FY22
Order book~₹14,000 cr, with ~₹1,700–1,800 cr incremental annual revenue potential from pipeline
Gross debt (consolidated)~₹1,500 cr gross, ~₹1,100 cr net; over two-thirds working capital
Pro forma working capital days215–220 days consolidated including Jayhawk; 240–250 days excluding Jayhawk
Standalone peak revenue potential from current gross block~₹3,500 cr
Maintenance capex guidance₹50–75 cr per year
Standalone tax rate guidance~25% going forward
Jayhawk pro forma annual revenue~US$76 million, consolidated 1 month and 2 days in Q4 FY26
Bliss GVS Pharma capacity utilization~30%, with top line around ₹1,000 cr
Bliss GVS Pharma peak revenue potential from current gross block~₹3,000 cr (per management arithmetic)